Our focus

Microbiota care

At Biocodex, we believe that understanding – and acting on – microbiota is important to the future of human health. Rooted in our heritage as pioneer in gut microbiota, we aim to become the global #1 in microbiota care.

Microbiota care

Since the launch of the world’s first probiotic drug, Saccharomyces boulardii CNCM I-745® in 1953, Biocodex has evolved from a pioneering French start-up to an global key player in the microbiota realm.
At Biocodex we are devoted to nurturing expertise in human microbiota and elevating their impact on our health. As a pioneer in therapeutic probiotics, we aim to become the leader in microbiota care.

Our focus on microbiota care is threefold:

1Solutions

Biocodex provides SOLUTIONS to improve microbiota health with our unique Saccharomyces boulardii CNCM I-745® probiotic drug, our innovative new Symbiosys® product range, and early-stage investment in start-up companies.

2Research

The Biocodex Microbiota Foundation advances SCIENTIFIC BREAKTHROUGHS by funding academic research in microbiota.

3Education

The Biocodex Microbiota Institute EDUCATES the general public and healthcare professionals on the growing importance of microbiota on healthcare and well-being.

Nicolas COUDURIER

Nicolas COUDURIER

Chief Executive Officer at BIOCODEX

We believe that understanding and acting on microbiota is key to the future human health, and we are committed to improving people’s well-being worldwide.

Biocodex’s solutions for microbiota care

We provide solutions protect, restore and reinforce the action of gut microbiome to treat and prevent human diseases or conditions. These solutions include:

The Biocodex Microbiota Institute

Screenshot of Biocodex Microbiota Institute website.

The Biocodex Microbiota Institute is an international knowledge hub dedicated to microbiota by:

  • Providing healthcare professionals with the latest scientific news and data including the Institute’s exclusive content such as Microbiota magazine, thematic folders, and interviews with experts…
  • Enlightening the general public on the importance of microbiota in healthcare and well-being ​
Visit the Biocodex Microbiata Institute website

The Biocodex Microbiota Foundation

The Biocodex Microbiota Foundation aims to enhance scientific knowledge on human microbiota and their interaction with various pathologies to help improve human health and well-being:

  • Contribute to the development of scientific knowledge in the field of microbiota.​
  • Encourage research.
  • Favor to improving people’s health and well-being worldwide. ​
Visit Biocodex Microbiata Foundation website

Want to know more?

2D zoomed image of the yeast Saccharomyces boulardii CNCM I-745 floating in the gut
About Us

Our heritage

Biocodex is a family-owned company founded 70 years ago to market the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Biocodex has since expanded its expertise in gut microbiota, evolving from French pioneer to an international player in the microbiota realm.

Father carries his baby boy on the shoulders while they walk through the field in the nature
Our focus

Orphan diseases

Biocodex develops and markets drugs for patients with severe orphan diseases. In the early 1990’s, we developed an anti-epileptic drug indicated for a newly discovered rare and severe epileptic disorder. Since then, we have been committed to raising awareness of rare epilepsies alongside healthcare professionals, patients and caregivers.

group of four young women looking and talking to each other outside.
Our focus

Women’s health

As a pioneer in feminine hygiene products and a market leader in France and Belgium, we aim to continue supporting women throughout the world daily and at every stage of their lives. We innovate constantly to bring effective solutions for women's health, comfort and well-being. Our commitment to women includes effective quality products, expert advice and a responsible attitude to the environment and society at large.